Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice

被引:3
作者
Sarawar, Sally [1 ]
Gabaglia, Claudia R. [1 ]
Sanchez, Adriana [1 ]
Hatta, Yasuko [2 ]
Dias, Peter [1 ]
Neumann, Gabriele [3 ]
Kawaoka, Yoshihiro [3 ,4 ,5 ]
Bilsel, Pamuk [2 ]
机构
[1] Biomed Res Inst Southern Calif, Oceanside, CA 92056 USA
[2] FluGen Inc, Madison, WI 53711 USA
[3] Univ Wisconsin, Influenza Res Inst, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53711 USA
[4] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Microbiol & Immunol,Div Virol, Tokyo 1088639, Japan
[5] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Special Pathogens, Tokyo 1088639, Japan
基金
美国国家卫生研究院;
关键词
influenza; vaccine; duration; antibody; heterosubtypic; depletion; A VIRUS; IMMUNITY; INFECTION; ANTIBODIES; PROTEIN; CELLS;
D O I
10.3390/vaccines10122131
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Seasonal influenza and the threat of global pandemics present a continuing threat to public health. However, conventional inactivated influenza vaccines (IAVs) provide little cross-protective immunity and suboptimal efficacy, even against well-matched strains. Furthermore, the protection against matched strains has been shown to be of a short duration in both mouse models and humans. M2SR (M2-deficient single-replication influenza virus) is a single-replication vaccine that has been shown to provide effective cross-protection against heterosubtypic influenza viruses in both mouse and ferret models. In the present study, we investigated the duration and mechanism of heterosubtypic protection induced by M2SR in a mouse model. We previously showed that M2SR generated from influenza A/Puerto Rico/8/34 (H1N1) significantly protected C57BL/6 mice against lethal challenge with both influenza A/Puerto Rico/8/34 (H1N1, homosubtypic) and influenza A/Aichi/2/1968 (H3N2, heterosubtypic), whereas the inactivated influenza vaccine provided no heterosubtypic protection. The homosubtypic protection induced by M2SR was robust and lasted for greater than 1 year, whereas that provided by the inactivated vaccine lasted for less than 6 months. The heterosubtypic protection induced by M2SR was of a somewhat shorter duration than the homosubtypic protection, with protection being evident 9 months after vaccination. However, heterosubtypic protection was not observed at 14 months post vaccination. M2SR has been shown to induce strong systemic and mucosal antibody and T cell responses. We investigated the relative importance of these immune mechanisms in heterosubtypic protection, using mice that were deficient in B cells or mice that were depleted of T cells immediately before challenge. Somewhat surprisingly, the heterosubtypic protection was completely dependent on B cells in this model, whereas the depletion of T cells had no significant effect on survival after a lethal heterosubtypic challenge. While antibody-dependent cellular cytotoxicity (ADCC) has been demonstrated to be important in the response to some influenza vaccines, a lack of Fc receptors did not affect the survival of M2SR-vaccinated mice following a lethal challenge. We examined the influenza proteins targeted by the heterosubtypic antibody response. Shortly after the H1N1 M2SR vaccination, high titers of cross-reactive antibodies to heterosubtypic H3N2 nucleoprotein (NP) and lower titers to the stalk region of the hemagglutinin (HA2) and neuraminidase (NA) proteins were observed. The high antibody titers to heterosubtypic NP persisted one year after vaccination, whereas the antibody titers to the heterosubtypic HA2 and NA proteins were very low, or below the limit of detection, at this time. These results show that the intranasal M2SR vaccine elicits durable protective immune responses against homotypic and heterosubtypic influenza infection not seen with intramuscular inactivated vaccines. Both the homo- and heterosubtypic protection induced by the single-replication vaccine are dependent on B cells in this model. While the homosubtypic protection is mediated by antibodies to the head region of HA, our data suggest that the heterosubtypic protection for M2SR is due to cross-reactive antibodies elicited against the NP, HA2, and NA antigens that are not targeted by current seasonal influenza vaccines.
引用
收藏
页数:13
相关论文
共 44 条
  • [21] Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection
    Padilla-Quirarte, H. O.
    Badillo-Godinez, O.
    Gutierrez-Xicotencatl, L.
    Acevedo-Betancur, Y.
    Luna-Andon, J. D.
    Montiel-Hernandez, J. L.
    Lopez-Guerrero, D. V.
    Esquivel-Guadarrama, F.
    VACCINE, 2019, 37 (19) : 2624 - 2633
  • [22] Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant
    Sui, Zhiwei
    Chen, Quanjiao
    Wu, Rui
    Zhang, Hongbo
    Zheng, Mei
    Wang, Hanzhong
    Chen, Ze
    ARCHIVES OF VIROLOGY, 2010, 155 (04) : 535 - 544
  • [23] Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
    Wang, Wenling
    Huang, Baoying
    Wang, Xiuping
    Tan, Wenjie
    Ruan, Li
    VIROLOGICA SINICA, 2019, 34 (05) : 583 - 591
  • [24] Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens
    Elaish, Mohamed
    Ngunjiri, John M.
    Ali, Ahmed
    Xia, Ming
    Ibrahim, Mahmoud
    Jang, Hyesun
    Hiremath, Jagadish
    Dhakal, Santosh
    Helmy, Yosra A.
    Jiang, Xi
    Renukaradhya, Gourapura J.
    Lee, Chang-Won
    PLOS ONE, 2017, 12 (02):
  • [25] Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus
    Lee, Yu-Na
    Kim, Min-Chul
    Lee, Young-Tae
    Kim, Yu-Jin
    Lee, Jongsang
    Kim, Cheol
    Ha, Suk-Hoon
    Kang, Sang-Moo
    ANTIVIRAL RESEARCH, 2015, 122 : 82 - 90
  • [26] PROTECTION OF MICE AGAINST INFLUENZA-A VIRUS CHALLENGE BY VACCINATION WITH BACULOVIRUS-EXPRESSED M2 PROTEIN
    SLEPUSHKIN, VA
    KATZ, JM
    BLACK, RA
    GAMBLE, WC
    ROTA, PA
    COX, NJ
    VACCINE, 1995, 13 (15) : 1399 - 1402
  • [27] Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant
    Zhiwei Sui
    Quanjiao Chen
    Rui Wu
    Hongbo Zhang
    Mei Zheng
    Hanzhong Wang
    Ze Chen
    Archives of Virology, 2010, 155 : 535 - 544
  • [28] Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles
    Gomes, Keegan Braz
    Vijayanand, Sharon
    Bagwe, Priyal
    Menon, Ipshita
    Kale, Akanksha
    Patil, Smital
    Kang, Sang-Moo
    Uddin, Mohammad N.
    D'Souza, Martin J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [29] An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus
    Hatta, Yasuko
    Hatta, Masato
    Bilsel, Pamuk
    Neumann, Gabriele
    Kawaoka, Yoshihiro
    VACCINE, 2011, 29 (12) : 2308 - 2312
  • [30] An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge
    Maryam Saleh
    Jamileh Nowroozi
    Behrokh Farahmand
    Fatemeh Fotouhi
    Biotechnology Letters, 2020, 42 : 1147 - 1159